Novo Nordisk A/S
- Country
- 🇩🇰Denmark
- Ownership
- Public
- Established
- 1923-01-01
- Employees
- 63.3K
- Market Cap
- $602.2B
- Website
- http://www.novonordisk.com
A Clinical Study to Compare the Efficacy and Safety of a Novel Medicine (NNC0268-0965) With Insulin Glargine
- Conditions
- Interventions
- First Posted Date
- 2020-10-05
- Last Posted Date
- 2024-01-10
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 86
- Registration Number
- NCT04575181
- Locations
- 🇩🇪
Profil Institut für Stoffwechselforschung GmbH, Neuss, Germany
🇩🇪Profil GmbH & Co. KG, Mainz, Germany
A Study Following Males With Haemophilia A on Prophylaxis With Esperoct®
- Conditions
- Interventions
- First Posted Date
- 2020-10-05
- Last Posted Date
- 2024-07-15
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 60
- Registration Number
- NCT04574076
- Locations
- 🇦🇹
AKH - Klin. Abt. f. Haematologie u. Haemostaseologie, Wien, Austria
🇬🇷"Laiko" General Hospital of Athens, Athens, Greece
🇭🇷KBC Zagreb, Rebro, Hemofilija centar, Zagreb, Croatia
Epidemiological Assessment of the Risk for Pancreatic Cancer Associated With the Use of Semaglutide in Patients With Type 2 Diabetes - A Cohort Study Based on Nordic Registry Data
- Conditions
- Interventions
- First Posted Date
- 2020-10-01
- Last Posted Date
- 2024-01-02
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 600000
- Registration Number
- NCT04572165
- Locations
- 🇩🇰
Novo Nordisk Investigational Site, Odense, Denmark
A Study to Look at the Safety of NNC0363-0845 in Healthy People and People With Type 1 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2020-09-30
- Last Posted Date
- 2023-06-27
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 68
- Registration Number
- NCT04569994
- Locations
- 🇩🇪
Novo Nordisk Investigational Site, Mainz, Germany
A Research Study to Compare a Medicine Called Semaglutide Against Placebo in People With Peripheral Arterial Disease and Type 2 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2020-09-23
- Last Posted Date
- 2024-11-13
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 792
- Registration Number
- NCT04560998
- Locations
- 🇦🇹
Universitätsklinik für Innere Medizin Graz, Graz, Austria
🇺🇸Angel City Research, Inc., Los Angeles, California, United States
🇩🇪Herz- und Diabeteszentrum NRW - Bad Oeynhausen, Bad Oeynhausen, Germany
A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Canada, as Part of Local Clinical Practice
- First Posted Date
- 2020-09-23
- Last Posted Date
- 2024-08-07
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 194
- Registration Number
- NCT04559815
- Locations
- 🇨🇦
Master Centre for Canada, Mississauga, Ontario, Canada
A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Switzerland, as Part of Local Clinical Practice
- First Posted Date
- 2020-09-03
- Last Posted Date
- 2024-02-12
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 194
- Registration Number
- NCT04537624
- Locations
- 🇨🇭
Master Centre Switzerland, Zurich, Oerlikon, Switzerland
A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Denmark, as Part of Local Clinical Practice
- First Posted Date
- 2020-09-03
- Last Posted Date
- 2024-01-10
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 99
- Registration Number
- NCT04537637
- Locations
- 🇩🇰
Novo Nordisk investigational site, Søborg, Denmark
🇩🇰Master Centre for Denmark, Copenhagen S, Denmark
Research Study Comparing New Tablets of Semaglutide in New Doses, in Healthy People
- First Posted Date
- 2020-08-24
- Last Posted Date
- 2023-10-10
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 290
- Registration Number
- NCT04524832
- Locations
- 🇩🇪
Novo Nordisk Investigational Site, Berlin, Germany
A Clinical Trial Comparing Semaglutide in Healthy People Who Eat and Take the Medicine at Different Times
- First Posted Date
- 2020-08-14
- Last Posted Date
- 2023-05-12
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 156
- Registration Number
- NCT04513704
- Locations
- 🇬🇧
Novo Nordisk Investigational Site, Harrow, United Kingdom